| EQIX |
Report |
2Q26 revenue |
BEAT |
pred ~$2.622B vs. cons $2.590B. |
MEDIUM |
| EQIX |
Report |
2Q26 adjusted EBITDA |
BEAT |
pred ~$1.405B vs. cons $1.370B. |
MEDIUM |
| EQIX |
Report |
2Q26 AFFO per diluted share |
BEAT |
pred ~$11.28 vs. cons $10.14. |
MEDIUM |
| EQIX |
Guide |
FY26 revenue guidance |
BETTER |
guide ~$10.30B vs. cons $10.24B (FY26). |
MEDIUM |
| EQIX |
Guide |
FY26 adjusted EBITDA guidance |
BETTER |
guide ~$5.29B vs. cons $5.23B (FY26). |
MEDIUM |
| EQIX |
Guide |
FY26 AFFO per diluted share guidance |
BETTER |
guide ~$43.40 vs. cons $43.05 (FY26). |
MEDIUM |
| EQIX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| EQIX |
Return |
5-day cumulative residual |
+0.5% (FADE) |
A ~$43.40 FY26 AFFO/share guide versus ~$43.05 consensus supports a positive initial reaction, but the incremental raise is modest and reported 2Q strength includes the delayed Hampton contribution; investors are likely to shift toward 2027 core recurring-growth, capex and return math after the initial beat. |
MEDIUM |